Ocular Therapeutix
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 267
- Market Cap
- $1.4B
- Introduction
Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.
Ocular Therapeutix accelerates timelines for SOL-1 Phase 3 trial of Axpaxli for wet AMD
Ocular Therapeutix accelerates SOL-1 Phase 3 trial for Axpaxli in wet AMD, now expected to complete randomization by end of 2024, with topline data in Q4 2025. The trial aims to compare Axpaxli implant with aflibercept injection for visual acuity maintenance.
Ocular Therapeutix™ Announces Accelerated Timelines for SOL-1 Registrational Trial
Ocular Therapeutix announces accelerated timelines for SOL-1 Phase 3 trial of AXPAXLI in wet AMD, expecting full enrollment by end of 2024 and topline data in Q4 2025. SOL-1 is a superiority study under a Special Protocol Agreement with the FDA, evaluating AXPAXLI's safety and efficacy compared to aflibercept.
Related Clinical Trials:
Sustained disease control with aflibercept 8 mg: a new benchmark in the management of ...
JFK, PL, CCW, TYW, XZ, PMW, SL, LB, ZH, SF, KWC, KR, and SS have various consulting roles, advisory board memberships, or research support from numerous pharmaceutical and medical technology companies.
© Copyright 2025. All Rights Reserved by MedPath